Gnr-055
Metabolic Diseases
AO GENERIUMPhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the Metabolic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide Anders Fink-Jensen, MD, DMSci | Phase 4 | A |
Semaglutide Nordsjaellands Hospital | Phase 4 | A |
Metformin Jinnah Sindh Medical University | Phase 4 | BBB |
Tirzepatide Washington University School of Medicine | Phase 4 | BBB |
PRAVASTATIN National Human Genome Research Institute (NHGRI) | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Gnr-055 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →